Skip to main content
NCBI home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1998 Apr;51(2):80–84. doi: 10.1136/mp.51.2.80

p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma.

G Busatto 1, Y H Shiao 1, A R Parenti 1, R Baffa 1, A Ruol 1, M Plebani 1, M Rugge 1
PMCID: PMC395614  PMID: 9713590

Abstract

BACKGROUND: Upregulation of the cell cycle associated genes, p16/CDKN2 and the retinoblastoma susceptibility gene (Rb), is commonly seen during the proliferation of normal cells. An inverse relation between the expression of p16/CDKN2 and Rb has been noted in many tumours, but has not yet been determined in oesophageal squamous carcinoma. AIMS: To investigate p16/CDKN2 genetic alterations and both the p16/CDKN2 and the Rb protein (pRb) immunophenotypes in oesophageal squamous carcinoma. METHODS: Twenty primary oesophageal squamous carcinomas were examined for mutations in p16/CDKN2 by the polymerase chain reaction, single stranded conformational polymorphism, and DNA sequencing. Synthesis of p16/CDKN2 and pRb proteins was determined by immunohistochemistry in 19 specimens of formalin fixed, paraffin wax embedded tissues. RESULTS: Mutations of p16/CDKN2 were not detected in exons 1 and 2. In only one case, G to C and C to T base changes were detected in a non-coding region of exon 3. Expression of p16/CDKN2 and Rb was observed in both normal and neoplastic areas of tissue sections, indicating neither consistent homozygous deletion nor consistent hypermethylation of the genes in tumours. Fourteen tumours showed an inverse expression of p16/CDKN2 and Rb. An increased percentage of cells that immunostained positively for p16/CDKN2 but not for pRb was observed in eight tumours, five of which had no detectable pRb, suggesting defective Rb expression in these oesophageal squamous carcinomas. CONCLUSIONS: These results indicate that p16/CDKN2 mutations occur infrequently in oesophageal squamous carcinoma. The alteration of the Rb gene is suggested as an important step in the development of these tumours.

Full Text

The Full Text of this article is available as a PDF (163.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beijersbergen R. L., Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta. 1996 Jun 7;1287(2-3):103–120. doi: 10.1016/0304-419x(96)00002-9. [DOI] [PubMed] [Google Scholar]
  2. Esteve A., Lehman T., Jiang W., Weinstein I. B., Harris C. C., Ruol A., Peracchia A., Montesano R., Hollstein M. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinog. 1993;8(4):306–311. doi: 10.1002/mc.2940080414. [DOI] [PubMed] [Google Scholar]
  3. Esteve A., Martel-Planche G., Sylla B. S., Hollstein M., Hainaut P., Montesano R. Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int J Cancer. 1996 May 3;66(3):301–304. doi: 10.1002/(SICI)1097-0215(19960503)66:3<301::AID-IJC5>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  4. Geradts J., Hu S. X., Lincoln C. E., Benedict W. F., Xu H. J. Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. Int J Cancer. 1994 Jul 15;58(2):161–167. doi: 10.1002/ijc.2910580203. [DOI] [PubMed] [Google Scholar]
  5. Geradts J., Kratzke R. A., Crush-Stanton S., Wen S. F., Lincoln C. E. Wild-type and mutant retinoblastoma protein in paraffin sections. Mod Pathol. 1996 Mar;9(3):339–347. [PubMed] [Google Scholar]
  6. Geradts J., Kratzke R. A., Niehans G. A., Lincoln C. E. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res. 1995 Dec 15;55(24):6006–6011. [PubMed] [Google Scholar]
  7. Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., Van Tornout J. M., Jones P. A. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995 Oct 15;55(20):4531–4535. [PubMed] [Google Scholar]
  8. Hong F. D., Huang H. J., To H., Young L. J., Oro A., Bookstein R., Lee E. Y., Lee W. H. Structure of the human retinoblastoma gene. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5502–5506. doi: 10.1073/pnas.86.14.5502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Igaki H., Sasaki H., Tachimori Y., Kato H., Watanabe H., Kimura T., Harada Y., Sugimura T., Terada M. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res. 1995 Aug 1;55(15):3421–3423. [PubMed] [Google Scholar]
  10. Jiang W., Zhang Y. J., Kahn S. M., Hollstein M. C., Santella R. M., Lu S. H., Harris C. C., Montesano R., Weinstein I. B. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9026–9030. doi: 10.1073/pnas.90.19.9026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kratzke R. A., Greatens T. M., Rubins J. B., Maddaus M. A., Niewoehner D. E., Niehans G. A., Geradts J. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996 Aug 1;56(15):3415–3420. [PubMed] [Google Scholar]
  12. Li Y., Nichols M. A., Shay J. W., Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994 Dec 1;54(23):6078–6082. [PubMed] [Google Scholar]
  13. Liu Q., Yan Y. X., McClure M., Nakagawa H., Fujimura F., Rustgi A. K. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene. 1995 Feb 2;10(3):619–622. [PubMed] [Google Scholar]
  14. Lukas J., Parry D., Aagaard L., Mann D. J., Bartkova J., Strauss M., Peters G., Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 1995 Jun 8;375(6531):503–506. doi: 10.1038/375503a0. [DOI] [PubMed] [Google Scholar]
  15. Maesawa C., Tamura G., Nishizuka S., Ogasawara S., Ishida K., Terashima M., Sakata K., Sato N., Saito K., Satodate R. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res. 1996 Sep 1;56(17):3875–3878. [PubMed] [Google Scholar]
  16. Medema R. H., Herrera R. E., Lam F., Weinberg R. A. Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6289–6293. doi: 10.1073/pnas.92.14.6289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995 Jul;1(7):686–692. doi: 10.1038/nm0795-686. [DOI] [PubMed] [Google Scholar]
  18. Mori T., Miura K., Aoki T., Nishihira T., Mori S., Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 1994 Jul 1;54(13):3396–3397. [PubMed] [Google Scholar]
  19. Okamoto A., Demetrick D. J., Spillare E. A., Hagiwara K., Hussain S. P., Bennett W. P., Forrester K., Gerwin B., Serrano M., Beach D. H. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11045–11049. doi: 10.1073/pnas.91.23.11045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Parry D., Bates S., Mann D. J., Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J. 1995 Feb 1;14(3):503–511. doi: 10.1002/j.1460-2075.1995.tb07026.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pollock P. M., Pearson J. V., Hayward N. K. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer. 1996 Feb;15(2):77–88. doi: 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  22. Rugge M., Bovo D., Busatto G., Parenti A. R., Fawzy S., Guido M., Ancona E., Ninfo V., Ruol A., Shiao Y. H. p53 alterations but no human papillomavirus infection in preinvasive and advanced squamous esophageal cancer in Italy. Cancer Epidemiol Biomarkers Prev. 1997 Mar;6(3):171–176. [PubMed] [Google Scholar]
  23. Sakaguchi M., Fujii Y., Hirabayashi H., Yoon H. E., Komoto Y., Oue T., Kusafuka T., Okada A., Matsuda H. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer. 1996 Feb 8;65(4):442–445. doi: 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  24. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
  25. Shiao Y. H., Rugge M., Correa P., Lehmann H. P., Scheer W. D. p53 alteration in gastric precancerous lesions. Am J Pathol. 1994 Mar;144(3):511–517. [PMC free article] [PubMed] [Google Scholar]
  26. Spruck C. H., 3rd, Gonzalez-Zulueta M., Shibata A., Simoneau A. R., Lin M. F., Gonzales F., Tsai Y. C., Jones P. A. p16 gene in uncultured tumours. Nature. 1994 Jul 21;370(6486):183–184. doi: 10.1038/370183a0. [DOI] [PubMed] [Google Scholar]
  27. Suzuki H., Zhou X., Yin J., Lei J., Jiang H. Y., Suzuki Y., Chan T., Hannon G. J., Mergner W. J., Abraham J. M. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Hum Mol Genet. 1995 Oct;4(10):1883–1887. doi: 10.1093/hmg/4.10.1883. [DOI] [PubMed] [Google Scholar]
  28. Tam S. W., Shay J. W., Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res. 1994 Nov 15;54(22):5816–5820. [PubMed] [Google Scholar]
  29. Tsuzuki T., Tsunoda S., Sakaki T., Konishi N., Hiasa Y., Nakamura M. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer. 1996 Jul 15;78(2):287–293. doi: 10.1002/(SICI)1097-0142(19960715)78:2<287::AID-CNCR15>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  30. Xu H. J., Hu S. X., Benedict W. F. Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene. 1991 Jul;6(7):1139–1146. [PubMed] [Google Scholar]
  31. Yang G., Zhang Z., Liao J., Seril D., Wang L., Goldstein S., Yang C. S. Immunohistochemical studies on Waf1p21, p16, pRb and p53 in human esophageal carcinomas and neighboring epithelia from a high-risk area in northern China. Int J Cancer. 1997 Sep 4;72(5):746–751. doi: 10.1002/(sici)1097-0215(19970904)72:5<746::aid-ijc7>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  32. Zhou X., Suzuki H., Shimada Y., Imamura M., Yin J., Jiang H. Y., Tarmin L., Abraham J. M., Meltzer S. J. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines. Genes Chromosomes Cancer. 1995 Aug;13(4):285–290. doi: 10.1002/gcc.2870130409. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES